Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Amicus Therapeutics announces new positive data on ATB200/AT2221 in Pompe disease; shares ahead 16% premarket

Published 10/04/2017, 08:05 AM
© Reuters. Amicus Therapeutics announces new positive data on ATB200/AT2221 in Pompe disease; shares ahead 16% premarket
FOLD
-
  • Amicus Therapeutics (NASDAQ:FOLD) announces additional positive data from its Phase 1/2 clinical trial assessing ATB200/AT2221 in patients with Pompe disease, an inherited lysosomal storage disorder. The results were presented at the World Muscle Society Conference in France.
  • After six months of treatment, muscle function improved in 88.9% (n=16/18) of patients and was stable in the other two. Six-minute walk test distance improved at month 6 and was durable to month 9.
  • Pulmonary function either improved or was stable at months 6 and 9.
  • ATB200/AT2221 is a new treatment paradigm consisting of ATB200, a recombinant human enzyme called acid alpha-glucosidase with enhanced uptake characteristics, and AT2221, a pharmacological chaperone that improves activity and stability.
  • Management will host a conference call this morning at 8:30 am ET to discuss the data.
  • Shares are up 16% premarket.
  • Previously: Amicus' ATB200/AT2221 shows treatment effect in early-stage Pompe study; shares ahead 7% premarket (May 15)
  • Now read: Move Over Yellen, It's Tax Cut Time!


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.